课题基金 / 基金详情

IMMUNOTHERAPY OF MALIGNANCY BY IN VIVO GENE TRANSFER INTO TUMORS

IMMUNOTHERAPY OF MALIGNANCY BY IN VIVO GENE TRANSFER INTO TUMORS
通过体内基因转移到肿瘤中的恶性肿瘤的免疫治疗
批准号：
6297168
负责人：
Gary J Nabel
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6297168
关键词：
MHC class I antigen clinical research clinical trial phase I drug screening /evaluation gene therapy human subject human therapy evaluation liposomes neoplasm /cancer genetics neoplasm /cancer immunotherapy transfection

项目摘要

项目成果

Gary J Nabel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Patients with advanced cancer will be treated by injection of a DNA/liposome complex directly within the tumor. DNA encoding an HLA-B7 histocompatibility antigen and the neomycin-resistant gene in a eukaryotic expression vector will be used. This is a phase I trial designed to assess safety of this gene therapy approach.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--VECTOR CONSTRUCTION
CORE--QUANTITATIVE MOLECULAR ANALYSIS
COMBINATION GENE TRANSFER, ANTIVIRAL TREATMENT & IMMUNOSTIMULATION FOR HIV+
IMMUNOTHERAPY BY IN VIVO GENE TRANSFER INTO TUMORS
海外基金